Gilead Sciences | GILD - Umlaufvermögen

Aktienkurs
143.92
Täglich Wechseln
-1.22 -0.84%
Monatlich
-5.12%
Jährlich
22.58%
Q1 Prognose
144.39




Umlaufvermögen Veränderung Datum
AbbVie USD 29.06B 523M 2025-12
Agios Pharmaceuticals USD 942.05M 91.06M 2025-12
ALKERMES USD 1.93B 187.5M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amgen USD 29.06B 1.17B 2025-12
Biogen USD 8.97B 37.5M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Coherus Biosciences USD 460.96M 80.75M 2025-09
Eli Lilly USD 55.63B 6.44B 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
GlaxoSmithKline GBP 17.51B 332M 2025-12
Glaxosmithkline GBP 23.98B 6.31B 2025-09
Incyte USD 5.02B 746.01M 2025-12
J&J USD 55.62B 1.01B 2025-12
Merck USD 47.56B 10.49B 2025-09
Moderna USD 6.54B 54M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novartis USD 28.2B 2.26B 2025-09
Pfizer USD 46.92B 3.22B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.95B 3.09B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
United Therapeutics USD 3.7B 208.5M 2025-12
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12